SynthesisMycopathologia2024
Systematic Review of Candidemia in Brazil: Unlocking Historical Trends and Challenges in Conducting Surveys in Middle-Income Countries.
Synthesis in Mycopathologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Biofilm formation efficiency by Candida species isolated from gastric mucosa of intragastric balloon patient under extremely low pH.Folia microbiologica · 2026Article
- Retrospective analysis of the epidemiological characteristics, risk factors, survival rate, and drug resistance of candidemia and construction of a logistic regression prediction model (2013-2024).BMC infectious diseases · 2026Article
- First Report of Fluconazole-Resistant Candida parapsilosis Harbouring the G458S ERG11p Substitution in a Brazilian Hospital.Mycoses · 2026Article
- Article
- Candidemia in a tertiary hospital in Southern Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Rezafungin in fluconazole-resistant and refractory candidiasis: the first Brazilian experience.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Nine-Year Surveillance ofJournal of fungi (Basel, Switzerland) · 2025Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Genetic Epidemiology and Resistance Investigations of Clinical Yeasts in Alexandria, Egypt.Pathogens (Basel, Switzerland) · 2025Article
- Detection and taxonomic identification of emerging pathogenic yeasts in surface waters from Lagoon Systems in Rio de Janeiro, Brazil.Environmental monitoring and assessment · 2025Article
- Candidemia in ICU Patients: What Are the Real Game-Changers for Survival?Journal of fungi (Basel, Switzerland) · 2025Article
- Management of Febrile Neutropenia in a Tropical Country.Hematology, transfusion and cell therapy · 2024Article
- Is candidemia mortality inevitable or a consequence of inadequate guideline adherence?The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionCandidemia, a bloodstream infection predominantly affecting critically ill patients, poses a significant global health threat especially with the emergence of non-albicans Candida species, including drug-resistant strains. In Brazil, limited access to advanced diagnostic tools and trained microbiologists hampers accurate identification of Candida species and susceptibility to antifungals testing hindering surveillance efforts.
methodsWe conducted a systematic review spanning publications from 2017 to 2023 addressing Candida species distribution and antifungal susceptibility among Brazilian patients with candidemia.
resultsDespite initially identifying 7075 records, only 16 met inclusion criteria providing accurate information of 2305 episodes of candidemia. The predominant species were C. albicans, C. parapsilosis, and C. tropicalis, followed by notable proportions of Nakaseomyces glabratus. Limited access to diagnostic tests was evident as only 5 out of 16 studies on candidemia were able to report antifungal susceptibility testing results. In vitro resistance to echinocandins was rare (only 6/396 isolates, 1,5%). In counterpart, fluconazole exhibited resistance rates ranging from 0 to 43%, with great heterogeneity among different studies and species of Candida considered.
conclusionOur review underscores the critical need for enhanced surveillance and research efforts to address the evolving landscape of candidemia and antifungal resistance in Brazil. Despite some limitations, available data suggest that while resistance to echinocandins and amphotericin B remains rare, there is a growing concern regarding resistance to fluconazole among Candida species.
Indexed as
Identifiers
38940953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.